Predictive genetic markers in gynaecological cancers: how to improve targeted therapy. KU Leuven
The development of more targeted therapies opened up a completely new era in treatment of gynaecological malignancies. However, little is known about the ideal position and timing in the treatment strategy and which patients in particular will benefit from treatments such as poly (ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint blockade (ICB). The aim of this proposal is to find (epi-)genetic markers that predict response to ...